QIAGEN has acquired additional licenses from Roche and Idaho Technology related to the use of instrumentation and reagents for PCR-based molecular testing. Reportedly, the agreements cover thermal cycler
Coughlin Stoia Geller Rudman & Robbins (Coughlin Stoia) has filed a class action in the US District Court for the Eastern District of Pennsylvania on behalf of purchasers
AEterna Zentaris has reported that Keryx, its partner and licensee for perifosine in the North American market, has received orphan-drug designation for the compound from the FDA for
The FDA has approved Sirion Therapeutics’ (Sirion) New Drug Application for Zirgan (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted
BioSpecifics Technologies (BioSpecifics) has reported that the Arthritis Advisory Committee appointed by the FDA has unanimously recommended that Xiaflex (collagenase clostridium histolyticum), a new orphan-designated, biologic, be granted
Oculus Innovative Sciences (Oculus) has entered into a new strategic partnership with V&M Industries for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the
The US Food and Drug Administration (FDA) has asked the manufacturers of the drug promethazine to include a boxed warning regarding the injectable form of the drug. The
Ozonics International has announced that a study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned.
PPD has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customised laboratory services in Southeast Asia. Steve
Clariant will build an ethoxylation plant in Dayabay, south of Guangzhou. The plant will be operational in early 2011 and will enable Clariant to meet increasing demand from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.